NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CellOrigin Biotech

CellOrigin Biotech

Private
HangzhouHealthcare & Life Scienceshttps://cell-origin.com

Last Round

Early Funding

Sep 21, 2023

Total Funding Raised

$13.8M

Company Overview

CellOrigin Biotech is a biotechnology company that develops genetically engineered iPSC-derived immune cell therapies for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

iPSCinduced pluripotent stem celloff-the-shelf cell therapyallogeneic cell therapyCAR-macrophageCAR-NKsolid tumor therapycancer immunotherapygene editingcell therapy platformoff-the-shelfnext-gen immunotherapybiotech R&Dclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CellOrigin Biotech Comparables

Compare CellOrigin Biotech with similar companies based on industry and business-model similarity.

CellOrigin Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shoreline Biosciences
89%
Neukio Biotherapeutics
87%
HebeCell
82%

CellOrigin Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingSep 21, 2023
Early FundingFeb 16, 2022
AngelJul 16, 2021

CellOrigin Biotech Investors

Notable investors and investment history

CellOrigin Biotech investors
InvestorRounds
Jifeng VenturesEarly Funding
Nest.BioAngel
Kunlun CapitalAngel
Shulan HealthAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 16, 2021

    Led by Kunlun Capital

CellOrigin Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CellOrigin Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CellOrigin Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range4
Year Founded2018
Last FundingSep 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.